The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors

Cancer Biology and Therapy

Volumn 7, Issue 12, 2008, Pages 1979-1981

  Ribeiro Oliveira Jr , Antônio ^a   Korbonits, Márta ^b   Grossman, Ashley B ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dopamine; Dopamine agonist; Dopamine receptors; Genes; Genetics; Neuroendocrine tumor; Oncology

Indexed keywords

CORTICOTROPIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; POLYPEPTIDE;

ARTICLE; CANCER SURVIVAL; DRUG EFFECT; DRUG MECHANISM; HORMONE ACTION; HUMAN; LIVER METASTASIS; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PREVALENCE; PROLACTINOMA; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 58149119393     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.12.7168     Document Type: Article

References (33)

1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
2. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007; 156:13-21.
3. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24:125-32.
4. Mantegani S, Brambilla E, Varasi M. Ergoline derivatives: receptor affinity and selectivity. Farmaco 1999; 54:288-96.
5. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002; 303:805-14.
6. 2 receptors. Biochem Biophys Res Commun 1999; 256:33-40.
7. 2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 2003; 209:61-9.
8. 4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. J Clin Endocrinol Metab 2001; 86:4460-7.
9. Mannelli M, Lazzeri C, Ianni L, La Villa G, Pupilli C, Bellini F, et al. Dopamine and sympathoadrenal activity in man. Clin Exp Hypertens 1997; 19:163-79.
10. Mannelli M, Pupilli C, Lanzillotti R, Ianni L, Amenta F, Ricci A, et al. Dopamine modulation of pathological human chromaffin tissue. Am J Hypertens 1990; 3:22-4.
11. Mannelli M, Pupilli C, Fabbri G, Musante R, De Feo ML, Franchi F, et al. Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans. J Clin Endocrinol Metab 1988; 66:626-31.
12. Ribeiro-de-Oliveira A Jr, Guerra RM, Foscolo RB, Marubayashi U, Reis AM, Coimbra CC. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol 1999; 162:237-42.
13. Balthazar CH, Ribeiro OA Jr, Marubayashi U, dos Reis AM, Coimbra CC. Chronic treatment with bromocriptine modifies metabolic adjustments in response to restraint stress in rats. Auton Autacoid Pharmacol 2007; 27:123-9.
14. 2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 2006; 35:50-63.
15. Saveanu A, Jaquet P. Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 2008.
16. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008; 37:67-99.
17. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 2004; 7:21-30.
18. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005; 28:21-7.
19. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89:2452-62.
20. 2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma. J Clin Endocrinol Metab 1994; 79:56-61.
21. Pivonello R, Ferone D, de Herder WW, De Krijger RR, Waaijers M, Mooij DM, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 2004; 89:4493-502.
22. 2 receptor imaging? Eur J Endocrinol 2006; 155:717-23.
23. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004; 89:1674-83.
24. Giusti M, Bocca L, Florio T, Foppiani L, Corsaro A, Auriati L, et al. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest 2000; 23:463-6.
25. Grossrubatscher E, Veronese S, Ciaramella PD, Pugliese R, Boniardi M, De Carlis L, et al. High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biology and Therapy 2008.
26. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72.
27. Lemmer K, Ahnert-Hilger G, Hopfner M, Hoegerle S, Faiss S, Grabowski P, et al. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci 2002; 71:667-78.
28. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006; 155:849-57.
29. Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, De Krijger RR, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007; 92:65-9.
30. Pathak RD, Tran TH, Burshell AL. A case of dopamine agonists inhibiting pancreatic polypeptide secretion from an islet cell tumor. J Clin Endocrinol Metab 2004; 89:581-4.
31. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008; 15:701-20.
32. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008; 286:238-50.
33. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinol 2008; 87:168-81.